AC Immune (ACIU) Upgraded at BidaskClub

BidaskClub upgraded shares of AC Immune (NASDAQ:ACIU) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday morning.

A number of other research firms have also commented on ACIU. UBS Group initiated coverage on shares of AC Immune in a research report on Friday, January 4th. They issued a buy rating and a $16.00 price objective for the company. Zacks Investment Research upgraded shares of AC Immune from a hold rating to a buy rating and set a $11.00 price objective for the company in a research report on Wednesday, November 21st. Finally, Leerink Swann initiated coverage on shares of AC Immune in a research report on Monday, November 12th. They issued an outperform rating and a $18.00 price objective for the company. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. AC Immune presently has a consensus rating of Buy and an average price target of $15.40.

Shares of ACIU traded down $0.05 during trading hours on Thursday, hitting $10.75. The company’s stock had a trading volume of 54,000 shares, compared to its average volume of 140,550. The company has a market capitalization of $708.02 million, a price-to-earnings ratio of -36.37 and a beta of 1.33. AC Immune has a 52-week low of $7.16 and a 52-week high of $17.40.



AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%. The company had revenue of $2.34 million during the quarter, compared to analyst estimates of $1.71 million. On average, research analysts expect that AC Immune will post -0.42 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in ACIU. Janus Henderson Group PLC bought a new position in shares of AC Immune in the third quarter valued at approximately $13,345,000. FMR LLC lifted its position in AC Immune by 28.9% during the third quarter. FMR LLC now owns 5,209,673 shares of the company’s stock valued at $41,678,000 after purchasing an additional 1,166,524 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in AC Immune during the third quarter valued at approximately $4,029,000. Citadel Advisors LLC bought a new stake in AC Immune during the third quarter valued at approximately $2,279,000. Finally, Artal Group S.A. lifted its position in AC Immune by 25.0% during the third quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $6,000,000 after purchasing an additional 150,000 shares during the last quarter. Institutional investors own 29.06% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Read More: Intrinsic Value and Stock Selection

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply